GSK Investigational Site

Dublin, Ohio 43017

0 studies enrolling now · 9 studies all time

What they study most

Asthma, Dermatitis, Atopic, Pulmonary Disease, Chronic Obstructive, Restless Legs Syndrome, Restless Legs Syndrome (RLS)

Studies at this site

• Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. — Stopped early
• A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis — Stopped early
• A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma — Completed
• A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma — Completed
• 12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome — Completed
• A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome — Completed
• Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome — Completed
• Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance — Completed